Neumora Therapeutics Touts Phase 1B NMRA-511 Gains in Alzheimer’s Agitation, Eyes Higher Doses

Neumora Therapeutics touts Phase 1B NMRA-511 gains in Alzheimer’s agitation, eyes higher doses

Neumora Therapeutics (NASDAQ:NMRA) reported top-line results from a Phase IB signal-seeking study of NMRA-511 in agitation associated with dementia due to Alzheimer’s disease, with management highlighting what it described as a clinically meaningful reduction in agitation scores and a favorable tole

Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial

The drug will advance to a multiple ascending dose study, with later plans to initiate a Phase II/III trial.The post Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial appeared first on Clinical Trials Arena.

Neumora's Alzheimer's Agitation Drug Shows Early Promise

Neumora Therapeutics, Inc. (NASDAQ:NMRA) on Monday shared results from its Phase 1b signal-seeking study of NMRA-511 for Alzheimer’s disease (AD) agitation. NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation. In the study, NMRA-511 demonstrated a favorable…